References
- Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-E386. https://doi.org/10.1002/ijc.29210
- Gallo A, Cha C. Updates on esophageal and gastric cancers. World J Gastroenterol 2006;12:3237-3242. https://doi.org/10.3748/wjg.v12.i20.3237
- Gunderson LL. Gastric cancer--patterns of relapse after surgical resection. Semin Radiat Oncol 2002;12:150-161. https://doi.org/10.1053/srao.2002.30817
- GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group, Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 2010;303:1729-1737. https://doi.org/10.1001/jama.2010.534
- Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357:1810-1820. https://doi.org/10.1056/NEJMoa072252
- Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 2011;29:4387-4393. https://doi.org/10.1200/JCO.2011.36.5908
- Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 2012;379:315-321. https://doi.org/10.1016/S0140-6736(11)61873-4
- Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010;17:1471-1474. https://doi.org/10.1245/s10434-010-0985-4
- Cho JH, Lim JY, Cho JY. Comparison of capecitabine and oxaliplatin with S-1 as adjuvant chemotherapy in stage III gastric cancer after D2 gastrectomy. PLoS One 2017;12:e0186362. https://doi.org/10.1371/journal.pone.0186362
- Fujitani K, Yang HK, Mizusawa J, Kim YW, Terashima M, Han SU, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol 2016;17:309-318. https://doi.org/10.1016/S1470-2045(15)00553-7
- Aoyama T, Kawabe T, Fujikawa H, Hayashi T, Yamada T, Tsuchida K, et al. Loss of lean body mass as an independent risk factor for continuation of S-1 adjuvant chemotherapy for gastric cancer. Ann Surg Oncol 2015;22:2560-2566. https://doi.org/10.1245/s10434-014-4296-z
- Yamashita K, Kurokawa Y, Yamamoto K, Hirota M, Kawabata R, Mikami J, et al. Risk factors for poor compliance with adjuvant S-1 chemotherapy for gastric cancer: a multicenter retrospective study. Ann Surg Oncol 2017;24:2639-2645. https://doi.org/10.1245/s10434-017-5923-2
- Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer 2017;20:1-19.
- Malet-Martino M, Martino R. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. Oncologist 2002;7:288-323. https://doi.org/10.1634/theoncologist.7-4-288
- Davis JL, Ripley RT. Postgastrectomy syndromes and nutritional considerations following gastric surgery. Surg Clin North Am 2017;97:277-293. https://doi.org/10.1016/j.suc.2016.11.005
- Iacovelli R, Pietrantonio F, Palazzo A, Maggi C, Ricchini F, de Braud F, et al. Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil: a meta-analysis of published trials. Br J Clin Pharmacol 2014;78:1228-1237. https://doi.org/10.1111/bcp.12449
- Berg P, McCallum R. Dumping syndrome: a review of the current concepts of pathophysiology, diagnosis, and treatment. Dig Dis Sci 2016;61:11-18. https://doi.org/10.1007/s10620-015-3839-x
- Ahmed H, Hammad AM, Abushouk AI, Zidan M, Salem M, Negida A, et al. Meta-analysis of safety and efficacy of rolapitant, NK-1 receptor antagonist for prevention of chemotherapy-induced nausea and vomiting. Curr Probl Cancer 2018;42:241-255. https://doi.org/10.1016/j.currproblcancer.2017.11.003
- Hayashi S, Fujii M, Takayama T. Prevention of postoperative small bowel obstruction in gastric cancer. Surg Today 2015;45:1352-1359. https://doi.org/10.1007/s00595-014-1106-y
- Schloss J, Colosimo M. B vitamin complex and chemotherapy-induced peripheral neuropathy. Curr Oncol Rep 2017;19:76. https://doi.org/10.1007/s11912-017-0636-z
- Rino Y, Oshima T, Yoshikawa T. Changes in fat-soluble vitamin levels after gastrectomy for gastric cancer. Surg Today 2017;47:145-150. https://doi.org/10.1007/s00595-016-1341-5
Cited by
- How Does Combined Resection Affect the Clinical Outcomes After Laparoscopic Surgery for Serosa-Positive Gastric Cancer?: A Retrospective Cohort Study to Investigate the Short-Term Outcomes of Laparosc vol.9, pp.None, 2018, https://doi.org/10.3389/fonc.2019.01564
- Facilitated completion of 1-year adjuvant S-1 monotherapy for pathological stage II or III gastric cancer by medical oncologists vol.50, pp.10, 2018, https://doi.org/10.1007/s00595-020-01995-8